Coronary Artery Disease

Icosapent ethyl significantly reduced coronary events and led to numerically fewer CV events at 5 years for patients with CAD and low plasma eicosapentaenoic acid already taking statin therapy, researchers reported.

Elixir Medical announced its novel sirolimus-eluting coronary implant adaptable to vessel physiology was granted a breakthrough device designation by the FDA.

Use of remdesivir in hospitalized patients with COVID-19 and reduced eGFR did not decrease the risk of major adverse cardiovascular events or major adverse kidney disease.

SAN DIEGO — Type 2 inflammation and asthma were significantly associated with higher risk for coronary artery disease, according to a presentation at the American Thoracic Society International Conference.

Semaglutide 2.4 mg improved symptoms and physical function in patients with obesity-related heart failure with preserved ejection fraction compared with placebo, regardless of diuretic use, according to new data from the STEP-HFpEF trials.

Patients with both diabetes and CAD appeared at significantly greater risk for dementia, especially vascular dementia, according to study findings published in European Journal of Preventive Cardiology.

A percutaneous approach to treatment of severe aortic stenosis and complex CAD was superior to surgical valve replacement and CABG, a speaker reported.

A drug-eluting coronary implant adaptable to vessel physiology with uncaging elements was linked to less target lesion failure and target vessel failure at 2 years compared with a drug-eluting stent, researchers reported.

Researchers have created a novel tool that predicts a person’s risk for cardiovascular complications after bone marrow transplantation.

ATLANTA — Use of a coronary sinus reducer improved chest pain symptoms and quality of life for patients with significant coronary artery disease, despite not improving myocardial blood flow, a speaker reported.